Literature DB >> 17680228

Cell isolation and expansion using Dynabeads.

Axl A Neurauter1, Mark Bonyhadi, Eli Lien, Lars Nøkleby, Erik Ruud, Stephanie Camacho, Tanja Aarvak.   

Abstract

This chapter describes the use of Dynabeads for cell isolation and expansion. Dynabeads are uniform polystyrene spherical beads that have been made magnetisable and superparamagnetic, meaning they are only magnetic in a magnetic field. Due to this property, the beads can easily be resuspended when the magnetic field is removed. The invention of Dynabeads made, by Professor John Ugelstad, has revolutionized the separation of many biological materials. For example, the attachment of target-specific antibodies to the surface of the beads allows capture and isolation of intact cells directly from a complex suspension such as blood. This is all accomplished under the influence of a simple magnetic field without the need for column separation techniques or centrifugation. In general, magnetic beads coated with specific antibodies can be used either for isolation or depletion of various cell types. Positive or negative cell isolation can be performed depending on the nature of the starting sample, the cell surface markers and the downstream application in question. Positive cell isolation is the method of choice for unprocessed samples, such as whole blood, and for downstream molecular applications. Positive cell isolation can also be used for any downstream application after detachment and removal of the beads. Negative cell isolation is the method of choice when it is critical that cells of interest remain untouched, i.e., no antibodies have been bound to any cell surface markers on the cells of interest. Some cell populations can only be defined by multiple cell surface markers. Such populations of cells can be isolated by the combination of negative and positive cell isolation. By coupling Dynabeads with antibodies directed against cell surface activation molecules, the beads can be used both for isolation and expansion of the cells. Dynabeads are currently used in two major clinical applications: 1) In the Isolex 300i Magnetic Cell Selection System for CD34 Stem Cell Isolation--2) For ex vivo T cell isolation and expansion using Dynabeads ClinExVivo CD3/CD28 for clinical trials in novel adoptive immunotherapy.

Entities:  

Mesh:

Year:  2007        PMID: 17680228     DOI: 10.1007/10_2007_072

Source DB:  PubMed          Journal:  Adv Biochem Eng Biotechnol        ISSN: 0724-6145            Impact factor:   2.635


  31 in total

1.  Circulating tumor cells: finding the needle in the haystack.

Authors:  Xiaoning Zhe; Michael L Cher; R Daniel Bonfil
Journal:  Am J Cancer Res       Date:  2011-06-01       Impact factor: 6.166

2.  A systematic evaluation of Schwann cell injection into acellular cold-preserved nerve grafts.

Authors:  Nithya J Jesuraj; Katherine B Santosa; Piyaraj Newton; Z Liu; Daniel A Hunter; Susan E Mackinnon; Shelly E Sakiyama-Elbert; Philip J Johnson
Journal:  J Neurosci Methods       Date:  2011-02-24       Impact factor: 2.390

Review 3.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

4.  Epigenome-wide association study of fasting blood lipids in the Genetics of Lipid-lowering Drugs and Diet Network study.

Authors:  Marguerite R Irvin; Degui Zhi; Roby Joehanes; Michael Mendelson; Stella Aslibekyan; Steven A Claas; Krista S Thibeault; Nikita Patel; Kenneth Day; Lindsay Waite Jones; Liming Liang; Brian H Chen; Chen Yao; Hemant K Tiwari; Jose M Ordovas; Daniel Levy; Devin Absher; Donna K Arnett
Journal:  Circulation       Date:  2014-06-11       Impact factor: 29.690

Review 5.  CTC clusters in cancer progression and metastasis.

Authors:  Anna Fabisiewicz; Ewa Grzybowska
Journal:  Med Oncol       Date:  2016-12-23       Impact factor: 3.064

6.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

7.  Magnetic Bead-Immobilized Mammalian Cells Are Effective Targets to Enrich Ligand-Displaying Yeast.

Authors:  Patrick S Lown; Benjamin J Hackel
Journal:  ACS Comb Sci       Date:  2020-04-27       Impact factor: 3.784

8.  Chromatin immunoprecipitation to detect DNA replication and repair factors.

Authors:  Mariana C Gadaleta; Osamu Iwasaki; Chiaki Noguchi; Ken-Ichi Noma; Eishi Noguchi
Journal:  Methods Mol Biol       Date:  2015

9.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

Review 10.  Adult stem cells and their trans-differentiation potential--perspectives and therapeutic applications.

Authors:  Sabine Hombach-Klonisch; Soumya Panigrahi; Iran Rashedi; Anja Seifert; Esteban Alberti; Paola Pocar; Maciej Kurpisz; Klaus Schulze-Osthoff; Andrzej Mackiewicz; Marek Los
Journal:  J Mol Med (Berl)       Date:  2008-07-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.